newsfilter
← Latest News
Business Wire·

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury